I thought it would be interesting to see the background of the recipients of Dr. Jay’s memo. Here is what I found. Looks like a Who’s Who in the world of HIV. This is a little long, but I thought some of the heavy-duty technical folks on the board would enjoy reading their bios. Some of their titles may have changed from what I found. Note references to NIH and one person formerly associated with The Bill & Melinda Gates Foundation.
Joseph J. Eron, MD, Professor of Medicine, Infectious Diseases; Chief, Division of Infectious Diseases; Director, Clinical Core, UNC Center for AIDS Research; Associate Director, General Clinical Research Unit; Adjunct Professor of Epidemiology, UNC Gillings School of Global Public Health. Current research interests include clinical development of combination antiretroviral therapy including novel agents, HIV resistance to antiretroviral therapy and the use of resistance testing and pharmacokinetic assessment to construct success therapy in treatment experienced patients. Additional interests include the study of primary (acute) HIV infection, HIV transmission and HIV penetration and antiretroviral penetration into tissue compartments such as genital track and central nervous system.
Dr. Michael Saag, University of AL Birmingham, Professor, Department of Medicine, Division of Infectious Diseases, Associate Dean, Global Health. He completed his residency and infectious disease and molecular virology fellowship training at the University of Alabama at Birmingham. During his fellowship training, Dr. Saag made seminal discoveries in the genetic evolution of HIV in vivo. He evaluated isolates of virus obtained from individual patients at different periods in time and cloned and molecularly characterized these isolates to determine the degree of diversity of co-existing viral variants and to describe their evolution over time. Dr. Saag has participated in many studies of antiretroviral therapy as well as novel treatments for opportunistic infections. He has published over 260 articles in peer reviewed journals.
Dr. Judith Feinberg, Univ. of Cincinnati, Assoc. Chair of Medicine for Faculty Development, Prof. of Clinical Development. Dr. Feinberg is nationally recognized for her clinical research in HIV infection and its opportunistic complications, and for her expertise in designing and conducting multicenter treatment trials. Dr. Feinberg's published works include approximately 98 original publications, 125 abstracts, and 10 book chapters.
Dr. Daniel Kuritzkes received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, HIV eradication and more recently, COVID-19.
Jonathan M Schapiro, MD has devoted his career to HIV clinical care, research and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine Center for AIDS Research, Stanford, CA. Dr. Schapiro Graduated from the Ben Gurion University School of Medicine and completed his Medicine Residency at the Rabin Medical Center in Israel. Dr. Schapiro’s research has focused on the causes of antiretroviral drug failure, interventions to optimize clinical care, and new drug development. His interests include resistance and cross-resistance between drugs, associations between resistance and pharmacology, development of new antiretroviral agents with improved resistance and pharmacological profiles, the clinical utility of resistance and drug level testing, and integrating resistance assays and other diagnostics into clinical care. Dr. Schapiro currently runs the HIV/AIDS clinic at the National Hemophilia Center in Tel Aviv, Israel.
Dr. Masur earned his undergraduate degree from Dartmouth College and his medical degree from Cornell University Medical College. He completed his internship and residency in internal medicine at New York Hospital and Johns Hopkins Hospital. Following a fellowship at Cornell in the Division of Infectious Diseases and Internal Medicine, he served as an Instructor and Assistant Professor of Medicine in the Infectious Diseases Division at Cornell from 1978 to 1982. He was recruited to NIH to jointly found a new department of critical care medicine and an HIV/AIDS program with the National Institute of Allergy and Infectious Diseases. He became Chief of the Critical Care Medicine Department in 1989.
John W. Mellors, MD, Dartmouth Medical School. Endowed Professor and Chief, Department of Medicine, Division of Infectious Diseases; Professor, Department of Pathology; Professor, Graduate School of Public Health, Department of Infectious Diseases and Microbiology; Executive Director, UPMC HIV/AIDS Program; Member, Molecular Virology and Microbiology Graduate Program. Dr. Mellors’ Lab focuses on mechanisms of HIV persistence and strategies to deplete the reservoirs of HIV that are the major barrier to curing the infection. The impact of innovative therapies on HIV reservoirs is being studied in Phase I/II trials of histone deacetylase inhibitors, monoclonal antibodies to immune checkpoint ligands, monoclonal antibodies to HIV envelope glycoproteins, and TLR agonists.
Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy. Dr. Deeks has published over 500 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection.
Paul Volberding, MD was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. He has worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. Dr. Volberding is a professor of medicine at UCSF. He is the co-director of the UCSF-Gladstone Center for AIDS Research, an NIH-funded program that supports a large variety of HIV related research across the entire University.
Robert T. Schooley, MD, is an infectious disease specialist and an expert in HIV and hepatitis C (HCV) infection and treatment. His research interests include influenza, global health and international medicine, and the diagnosis and management of infections that cause death and morbidity in resource-limited settings. Dr. Schooley is particularly interested in the origin and development (pathogenesis) of HIV and HIV therapy, and was one of the first researchers to describe the humoral and cellular immune responses to HIV infection. Dr. Schooley is a professor in the Division of Infectious Diseases within the Department of Medicine at UC San Diego School of Medicine, where he has developed a multidisciplinary research program for hepatitis C.
(Note: I am not certain this is the right Dr. Becker as Dr. Jay used a gmail ID for his email.) Stephen Becker is an experienced physician-leader with global expertise in HIV public health. He has demonstrated leadership in multiple areas of HIV treatment and prevention, on both global and US domestic levels. He has led, and advised, multiple programs involving government health and research agencies, donor and implementer organizations, academic, NGO and private sector pharmaceutical and diagnostic entities. In his previous role at the Bill & Melinda Gates foundation he led HIV prevention and treatment optimization programs, and championed a new philanthropic model, focusing on evidence-based decision making and coordination of research and development efforts with those of programmatic adoption and implementation. He currently works as a consultant to HIV-related NGOs, the NIH, academic groups and pharma in areas of HIV prevention and treatment optimization.
(Note: I am not certain this is the correct Dr. Hardy as Dr. Jay used a gmail ID for his email.) David Hardy, MD, is an Adjunct Professor of Medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA and as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C.
Drs. Seethamraju, Patterson, Yang, and Recknor are known on this board.
Kimberly Struble, PharmD, is currently a Senior Clinical Analyst Team Leader in the Division of Antivirals in the Office of Infectious Diseases, CDER, FDA.
Debra Birnkrant, M.D., Director, Division of Antivirals (DAV), Office of Infectious Diseases (OID), Center for Drug Evaluation and Research (CDER)
Jeffrey Murray, M.D., M.P.H, Deputy Director, Division of Antivirals (DAV), Office of Infectious Diseases (OID), Center for Drug Evaluation and Research (CDER)
Dr. Woodcock does not need an introduction to this board.
Joseph J. Eron, MD, Professor of Medicine, Infectious Diseases; Chief, Division of Infectious Diseases; Director, Clinical Core, UNC Center for AIDS Research; Associate Director, General Clinical Research Unit; Adjunct Professor of Epidemiology, UNC Gillings School of Global Public Health. Current research interests include clinical development of combination antiretroviral therapy including novel agents, HIV resistance to antiretroviral therapy and the use of resistance testing and pharmacokinetic assessment to construct success therapy in treatment experienced patients. Additional interests include the study of primary (acute) HIV infection, HIV transmission and HIV penetration and antiretroviral penetration into tissue compartments such as genital track and central nervous system.
Dr. Michael Saag, University of AL Birmingham, Professor, Department of Medicine, Division of Infectious Diseases, Associate Dean, Global Health. He completed his residency and infectious disease and molecular virology fellowship training at the University of Alabama at Birmingham. During his fellowship training, Dr. Saag made seminal discoveries in the genetic evolution of HIV in vivo. He evaluated isolates of virus obtained from individual patients at different periods in time and cloned and molecularly characterized these isolates to determine the degree of diversity of co-existing viral variants and to describe their evolution over time. Dr. Saag has participated in many studies of antiretroviral therapy as well as novel treatments for opportunistic infections. He has published over 260 articles in peer reviewed journals.
Dr. Judith Feinberg, Univ. of Cincinnati, Assoc. Chair of Medicine for Faculty Development, Prof. of Clinical Development. Dr. Feinberg is nationally recognized for her clinical research in HIV infection and its opportunistic complications, and for her expertise in designing and conducting multicenter treatment trials. Dr. Feinberg's published works include approximately 98 original publications, 125 abstracts, and 10 book chapters.
Dr. Daniel Kuritzkes received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, HIV eradication and more recently, COVID-19.
Jonathan M Schapiro, MD has devoted his career to HIV clinical care, research and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine Center for AIDS Research, Stanford, CA. Dr. Schapiro Graduated from the Ben Gurion University School of Medicine and completed his Medicine Residency at the Rabin Medical Center in Israel. Dr. Schapiro’s research has focused on the causes of antiretroviral drug failure, interventions to optimize clinical care, and new drug development. His interests include resistance and cross-resistance between drugs, associations between resistance and pharmacology, development of new antiretroviral agents with improved resistance and pharmacological profiles, the clinical utility of resistance and drug level testing, and integrating resistance assays and other diagnostics into clinical care. Dr. Schapiro currently runs the HIV/AIDS clinic at the National Hemophilia Center in Tel Aviv, Israel.
Dr. Masur earned his undergraduate degree from Dartmouth College and his medical degree from Cornell University Medical College. He completed his internship and residency in internal medicine at New York Hospital and Johns Hopkins Hospital. Following a fellowship at Cornell in the Division of Infectious Diseases and Internal Medicine, he served as an Instructor and Assistant Professor of Medicine in the Infectious Diseases Division at Cornell from 1978 to 1982. He was recruited to NIH to jointly found a new department of critical care medicine and an HIV/AIDS program with the National Institute of Allergy and Infectious Diseases. He became Chief of the Critical Care Medicine Department in 1989.
John W. Mellors, MD, Dartmouth Medical School. Endowed Professor and Chief, Department of Medicine, Division of Infectious Diseases; Professor, Department of Pathology; Professor, Graduate School of Public Health, Department of Infectious Diseases and Microbiology; Executive Director, UPMC HIV/AIDS Program; Member, Molecular Virology and Microbiology Graduate Program. Dr. Mellors’ Lab focuses on mechanisms of HIV persistence and strategies to deplete the reservoirs of HIV that are the major barrier to curing the infection. The impact of innovative therapies on HIV reservoirs is being studied in Phase I/II trials of histone deacetylase inhibitors, monoclonal antibodies to immune checkpoint ligands, monoclonal antibodies to HIV envelope glycoproteins, and TLR agonists.
Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy. Dr. Deeks has published over 500 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection.
Paul Volberding, MD was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. He has worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. Dr. Volberding is a professor of medicine at UCSF. He is the co-director of the UCSF-Gladstone Center for AIDS Research, an NIH-funded program that supports a large variety of HIV related research across the entire University.
Robert T. Schooley, MD, is an infectious disease specialist and an expert in HIV and hepatitis C (HCV) infection and treatment. His research interests include influenza, global health and international medicine, and the diagnosis and management of infections that cause death and morbidity in resource-limited settings. Dr. Schooley is particularly interested in the origin and development (pathogenesis) of HIV and HIV therapy, and was one of the first researchers to describe the humoral and cellular immune responses to HIV infection. Dr. Schooley is a professor in the Division of Infectious Diseases within the Department of Medicine at UC San Diego School of Medicine, where he has developed a multidisciplinary research program for hepatitis C.
(Note: I am not certain this is the right Dr. Becker as Dr. Jay used a gmail ID for his email.) Stephen Becker is an experienced physician-leader with global expertise in HIV public health. He has demonstrated leadership in multiple areas of HIV treatment and prevention, on both global and US domestic levels. He has led, and advised, multiple programs involving government health and research agencies, donor and implementer organizations, academic, NGO and private sector pharmaceutical and diagnostic entities. In his previous role at the Bill & Melinda Gates foundation he led HIV prevention and treatment optimization programs, and championed a new philanthropic model, focusing on evidence-based decision making and coordination of research and development efforts with those of programmatic adoption and implementation. He currently works as a consultant to HIV-related NGOs, the NIH, academic groups and pharma in areas of HIV prevention and treatment optimization.
(Note: I am not certain this is the correct Dr. Hardy as Dr. Jay used a gmail ID for his email.) David Hardy, MD, is an Adjunct Professor of Medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA and as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C.
Drs. Seethamraju, Patterson, Yang, and Recknor are known on this board.
Kimberly Struble, PharmD, is currently a Senior Clinical Analyst Team Leader in the Division of Antivirals in the Office of Infectious Diseases, CDER, FDA.
Debra Birnkrant, M.D., Director, Division of Antivirals (DAV), Office of Infectious Diseases (OID), Center for Drug Evaluation and Research (CDER)
Jeffrey Murray, M.D., M.P.H, Deputy Director, Division of Antivirals (DAV), Office of Infectious Diseases (OID), Center for Drug Evaluation and Research (CDER)
Dr. Woodcock does not need an introduction to this board.
24
